Introduction: Dual bronchodilator therapy is reserved as a second-line treatment in patients
INTRODUCTION
There is evidence to suggest that early initiation of maintenance bronchodilator therapy in patients with chronic obstructive pulmonary disease (COPD) may provide benefits in lung function and health status [1] [2] [3] . A recent study also reported that dual-bronchodilator maintenance therapy with a long-acting muscarinic antagonist (LAMA) plus a long-acting b 2 -agonist (LABA) may provide improvements in lung function in treatment-naïve patients and patients with less severe COPD, as well as those already receiving maintenance therapy [4] .
Since many patients with COPD with moderate lung function impairment remain symptomatic with mono-bronchodilator therapy [5] , a rationale for the use of dual bronchodilators in these patients is emerging.
The effects of early initiation of maintenance therapy with long-acting bronchodilators are not yet fully characterized, and fundamental questions remain regarding the most appropriate timing of maintenance bronchodilator therapy initiation for COPD and which patients would benefit most from dual-bronchodilator treatment versus monotherapy. To assess these points it is important to consider not just improvements but also the risk of deterioration in both lung function and health status in COPD with dual-bronchodilator versus standard LAMA monotherapy when used as either first-or second-line therapy.
Short-term clinically important deterioration (CID) is a new composite endpoint in COPD,
which encompasses the occurrence of clinically significant, recognized deteriorations (termed minimal clinically important differences) in lung function, quality of life (QoL), and moderate-to-severe exacerbations that can be used as a measure of disease worsening [6] [7] [8] [9] . This composite endpoint is consistent with current Global initiative for chronic
Obstructive Lung Disease (GOLD) guidelines [10] , which recommend that lung function, health status, and COPD exacerbation risk are considered when assessing disease progression and severity. There are currently limited objective means to assess symptomatic patients at an early stage in the course of COPD; therefore, assessment of CID may provide useful information on how to maintain patient stability and prevent deterioration. 
METHODS

Study Design, Treatments, and Patients
This was a post hoc analysis (GSK analysis: 202066) of data from three multicenter, randomized, 24-week, parallel-group, blinded trials selected because they compared UMEC/VI and TIO: ZEP117115 (NCT01777334) [11] , DB2113374 (NCT01316913) [12] , and DB2113360 (NCT01316900) [12] . Data were included in the analysis, but results are not presented in this manuscript [11, 12] .
Patients were aged C40 years, had a diagnosis of symptomatic COPD [13] an FEV 1 decrease C100 ml or an SGRQ total score increase C4 units from baseline on two consecutive visits, or for C50% of all available subsequent visits. As the protocols from the studies mandated that patients be withdrawn from the study following a moderate-to-severe COPD exacerbation, the first incidence of a moderate-to-severe COPD exacerbation was also considered a component of sustained CID. In each study, adverse events (AEs) were monitored.
Statistical Analysis
Statistical comparisons were presented for UMEC/VI 62.5/25 mcg versus TIO. Trough 
RESULTS
Study Population
The ITT population in the UMEC/VI 62. (Fig. 1) .
Health-related quality of life: UMEC/VI and TIO provided mean improvements (C4-unit decrease) from baseline in total SGRQ score, in (13) 106 (12) 17 (6) 22 (9) ICS use at screening (Fig. 2) . In the smaller MN population, the SGRQ treatment differences were in favor of UMEC/ VI at all time points, but were not significant (Fig. 2) .
The odds of being an SGRQ responder (C4-unit decrease) versus a non-responder was significantly greater with UMEC/VI treatment compared with TIO treatment at days 28 and 84 in the ITT population (OR: 1.3 at both time points; P = 0.007 day 28; P = 0.009 day 84), but was not significantly different in the MN population (Table S1 ). At day 168, the odds of being a responder versus a non-responder were not significantly different between treatment groups in either the MN or ITT populations (Table S1 ). (Fig. 3) .
When the individual components of a first short-term CID were assessed, a significant reduction in the risk of deterioration in lung function was observed for UMEC/VI treatment versus TIO in both the MN and ITT Table 3 ). The risk of a CID on SGRQ total score was also significantly reduced with UMEC/VI treatment compared with TIO, but only in the ITT population (Table 3 ). There was no significant difference between the treatment groups in the risk of a moderate-to-severe exacerbation in either population. This study also assessed the effect of UMEC/ VI and TIO treatment on the composite endpoint of short-term CID, which is designed to address clinically important early signs of deterioration in lung function, health status, and/or COPD exacerbations. A recent study has demonstrated the dual bronchodilator therapy may reduce the risk of short-term CID and potentially provide greater airway stability compared with monotherapy [15] .
One additional potential advantage of the CID approach is that it provides a means to assess symptomatic patients, including MN patients at risk of deterioration at an early stage in the course of COPD, potentially providing useful information on how to prevent deterioration and maintain stability or when to escalate therapy.
This analysis demonstrated that UMEC/VI reduced the risk of a first composite short-term CID compared with TIO to a similar extent in both the ITT and MN populations. These AEs reported by C3% of patients on any treatment, n(%) Nasopharyngitis 63 (7) 62 (7) 18 (7) 15 (6) Headache 80 (9) 55 (6) 20 (7) 15 (6) Back pain 27 (3) 28 (3) 8 (3) 4 (2) Cough 25 (3) 26 (3) 5 (2) 8 (3) Upper respiratory tract infection 17 (2) 26 (3) 2 (\1) 10 (4) AEs of special interest
On-treatment non-fatal SAEs Any event, n(%) 42 (5) 35 (4) 8 (3) 11 (4 [3, 18] . In a previous publication, which examined time to a first CID with UMEC/VI versus TIO and placebo in both GOLD B and D subgroups, no apparent differences were found in the magnitude of treatment benefit on the incidence of CID based on levels of lung function impairment or disease severity at baseline [15] . The current study focused on patients from three similar studies with a large proportion of symptomatic COPD patients (all mMRC C2), 55% and 45% of the ITT and MN subgroups, respectively, presenting with severe lung function impairment at baseline. The current findings are commensurate with the earlier study by Singh and colleagues [15] , highlighting that reducing the risk of a first CID is as likely in low and high risk patients and when using dual bronchodilators as first-or second-line therapy. comparing UMEC/VI and TIO, and all patients had a low exacerbation risk. Consequently, it is possible that patients who are less symptomatic than those studied here could be managed on monotherapy.
Also, exacerbations as a deterioration parameter had limited potential to feature strongly in this short-term analysis. Therefore, a longer follow-up may mean that exacerbations feature more prominently in the CID endpoint in low-risk patients receiving bronchodilators without concurrent ICS. Whilst the occurrence of short-term CID has been linked with long-term poor outcomes, further validation of the CID endpoint in prospective trials of increased duration are needed to better understand long-term outcomes in COPD with dualversus mono-bronchodilator therapy.
